Trial Profile
Immunomodulation of Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) After Platinum Failure
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2022 Status changed from active, no longer recruiting to completed.
- 13 Jun 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 13 Jun 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.